The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.

The present invention provides chimeric ectolysins useful for selective suppression of certain targeted bacterial species while having little to no effect on closely related non-targeted bacterial species. Specifically, the disclosure provides polypeptides for selective suppression of growth of Staphylococcus aureus and/or S. hominis but not S. epidermidis. Compositions and methods for selective suppression of target bacterial species are also provided.

In certain embodiments, the present invention provides isolated replication defective non-integrating segmented viruses comprising a genome where at least one of the viral segments comprises a heterologous nucleotide sequence comprising a nucleotide segment that encodes an effector protein. Also provided are methods of using these viruses.

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

Provided are modified Staphylococcus aureus pathogenicity islands of a variety of types and origins. The pathogenicity island are characterized as having a polynucleotide comprising a bacterial pathogenicity island nucleotide sequence (a “B-PINS”) that contains one or more modifications (“modified B-PINS”), that include i) a deletion or disruption of at least one virulence determinant of the B-PINS; and ii) an insertion of at least one cargo sequence. The polynucleotide are capable of being packaged within a bacterium into a phage-like particle that comprises a bacteriophage capsid, tail and tail fiber proteins in the form of an antibacterial drone (“ABD”). The ABD is capable of infecting bacteria such that at least one cargo sequence is introduced into bacteria infected by the ABD. Pharmaceutical and other compositions the ABDs are also included. Bacteria that make the ABDs are provided, as are isolated and/or purified ABDs. Methods of killing or otherwise modifying bacteria using the ABDs are also provided.

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.

Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.

The present invention provides methods, assays, compositions, formulations, and constructs, particularly lytic peptide constructs, which relate to and are based on the activity and use of blood components, particularly serum albumin and lysozyme, and their activity and use to enhance or synergize with the bacterial killing effect of anti-bacterial lytic proteins and peptides.